<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284555</url>
  </required_header>
  <id_info>
    <org_study_id>XF-MupC01</org_study_id>
    <nct_id>NCT02284555</nct_id>
  </id_info>
  <brief_title>Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)</brief_title>
  <official_title>A Single Centre, Open, Non-controlled Study in Healthy Subjects to Assess the Eradication of Nasal Carriage of Staphylococcus Aureus (SA) Following a Five Day Course of Mupirocin (Bactroban 2% Nasal Ointment) Using a Broth Enriched Culture Microbiological Assessment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Destiny Pharma Plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Destiny Pharma Plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the nasal eradication of SA in healthy subjects following treatment&#xD;
      with mupirocin 2% (Bactroban 2% Nasal Ointment) twice daily for 5 days, by means of a broth&#xD;
      enriched culture microbial assay. The sensitivities of broth enrichment and plating assay&#xD;
      methods will be compared. The safety and tolerability of Bactroban 2% Nasal Ointment will&#xD;
      also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apparent Eradication of Nasal Carriage of SA</measure>
    <time_frame>48 hours after the last dose of mupirocin 2%</time_frame>
    <description>Apparent eradication demonstrated by a semi-quantitative score of negative or zero using a broth enriched culture microbial assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects With Adverse Events and Changes in Vital Signs, ECG and Routine Haematology, Clinical Chemistry and Urinalysis Tests Assessed Over the Five Day Treatment Period and Follow-up at 7 and 14 Days Relative to the First Dose.</measure>
    <time_frame>5 day treatment period and follow-up at 7 and 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Staphylococcal Infection</condition>
  <arm_group>
    <arm_group_label>Mupirocin 2% nasal Ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mupirocin</intervention_name>
    <description>Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.</description>
    <arm_group_label>Mupirocin 2% nasal Ointment</arm_group_label>
    <other_name>Bactroban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Normal, healthy male or female subjects aged between 18 and 75 years.&#xD;
&#xD;
          2. Subjects confirmed to be persistent nasal SA carriers, defined by 3 separate, SA&#xD;
             positive cultures from nasal swabs. Two positive cultures should be obtained at&#xD;
             screening visits up to 12 weeks prior to inclusion and at least two weeks apart. The&#xD;
             final confirmatory culture should be obtained from a baseline nasal swab prior to&#xD;
             administration of the first dose.&#xD;
&#xD;
          3. Subjects who are able and willing to provide written informed consent to participate&#xD;
             in the study&#xD;
&#xD;
          4. Subjects who have a body mass index (BMI) ≥18.5 kg/m2 and ≤ 32 kg/m2.&#xD;
&#xD;
          5. Subjects who agree not to take part in another clinical trial at any time during the&#xD;
             study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are or may be pregnant or who are lactating.&#xD;
&#xD;
          2. Subjects who have any acute or chronic illness or infection.&#xD;
&#xD;
          3. Subjects who have smoked within the 3 months prior to screening (confirmed by urinary&#xD;
             cotinine test).&#xD;
&#xD;
          4. Subjects who are females of child-bearing potential, defined as being physiologically&#xD;
             capable of becoming pregnant, UNLESS using one or more of the following acceptable&#xD;
             methods of contraception; established use of oral, injected or implanted hormonal&#xD;
             contraception, intrauterine Device (IUD or Coil AND barrier Method (condom or&#xD;
             diaphragm or cervical/vault cap) plus spermicidal cream/gel. Contraceptive use should&#xD;
             continue throughout the study and for 1 month following completion of the study.&#xD;
&#xD;
          5. Subjects who are fertile males, defined as all males physiologically capable of&#xD;
             conceiving offspring, UNLESS the subject agrees to comply with acceptable&#xD;
             contraception e.g. condom plus spermicidal cream/gel. Contraceptive use should&#xD;
             continue throughout the study and for 3 months following completion of the study.&#xD;
&#xD;
          6. Subject with any open wound, lesion, inflammation, erythema or infection affecting the&#xD;
             nostrils, nose, upper lip and area of skin close to the nose. This includes herpes&#xD;
             simplex lesions and discoid lupus.&#xD;
&#xD;
          7. Subjects who have a currently symptomatic upper respiratory tract infection,&#xD;
             nasopharyngitis, influenza or condition involving increase in nasal secretion such as&#xD;
             seasonal or chronic, allergic rhinitis.&#xD;
&#xD;
          8. Subjects with a history of drug or alcohol abuse in the previous 12 months or who have&#xD;
             a positive urine drug test for substances of abuse.&#xD;
&#xD;
          9. Subjects with a known clinically significant history of atopy or hypersensitivity to&#xD;
             any drug or latex.&#xD;
&#xD;
         10. Subjects with a history of serious illness, cancer or psychiatric condition.&#xD;
&#xD;
         11. Subjects who have been treated with or have taken any prescribed or over-the-counter&#xD;
             medication within the previous 14 days, with the exception of hormonal contraceptives&#xD;
             or hormone replacement therapy.&#xD;
&#xD;
         12. Subjects who have taken or used topical or systemic antibiotics within the month prior&#xD;
             to screening.&#xD;
&#xD;
         13. Subjects who are known to have serum hepatitis, or who are carriers of the hepatitis B&#xD;
             surface antigen (HBsAg) or hepatitis C antibody, or who have a positive result to the&#xD;
             test for human immunodeficiency virus (HIV) antibodies&#xD;
&#xD;
         14. Subjects who have participated in a clinical trial within the last 3 months.&#xD;
&#xD;
         15. Subjects with any clinically significant abnormality in vital signs or laboratory&#xD;
             analyses at screening or at baseline, based on the opinion of the investigator.&#xD;
&#xD;
         16. Subjects with nasal polyps or significant anatomical nasal abnormality.&#xD;
&#xD;
         17. Subjects with a history of nasal surgery, including cauterization in the last 12&#xD;
             months.&#xD;
&#xD;
         18. Subjects with a history of multiple episodes [&gt;3] of epistaxis within the last 12&#xD;
             months.&#xD;
&#xD;
         19. Subjects with in-situ nasal jewellery or open nasal piercings.&#xD;
&#xD;
         20. Subjects with a history of abnormal bleeding, bruising, frequent nosebleeds or a&#xD;
             diagnosis of von Willebrand disease.&#xD;
&#xD;
         21. Subjects who have or have had an autoimmune disease.&#xD;
&#xD;
         22. Subjects with hypersensitivity to any of the ingredients of Bactroban® Nasal Ointment&#xD;
             i.e. mupirocin, white soft paraffin, Softisan 649 (mixed diglycerinester of fatty&#xD;
             acids).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Mr Hayter, BSc</last_name>
    <role>Study Director</role>
    <affiliation>Destiny Pharma Plc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec Reseach Ltd</name>
      <address>
        <city>Wales</city>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <results_first_submitted>February 2, 2016</results_first_submitted>
  <results_first_submitted_qc>February 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2016</results_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mupirocin 2% Nasal Ointment</title>
          <description>Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).&#xD;
Mupirocin: Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mupirocin 2% Nasal Ointment</title>
          <description>Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).&#xD;
Mupirocin: Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.8" spread="14.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apparent Eradication of Nasal Carriage of SA</title>
        <description>Apparent eradication demonstrated by a semi-quantitative score of negative or zero using a broth enriched culture microbial assay.</description>
        <time_frame>48 hours after the last dose of mupirocin 2%</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mupirocin 2% Nasal Ointment</title>
            <description>Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).&#xD;
Mupirocin: Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Eradication of Nasal Carriage of SA</title>
          <description>Apparent eradication demonstrated by a semi-quantitative score of negative or zero using a broth enriched culture microbial assay.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects With Adverse Events and Changes in Vital Signs, ECG and Routine Haematology, Clinical Chemistry and Urinalysis Tests Assessed Over the Five Day Treatment Period and Follow-up at 7 and 14 Days Relative to the First Dose.</title>
        <time_frame>5 day treatment period and follow-up at 7 and 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mupirocin 2% Nasal Ointment</title>
            <description>Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).&#xD;
Mupirocin: Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Adverse Events and Changes in Vital Signs, ECG and Routine Haematology, Clinical Chemistry and Urinalysis Tests Assessed Over the Five Day Treatment Period and Follow-up at 7 and 14 Days Relative to the First Dose.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mupirocin 2% Nasal Ointment</title>
          <description>Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).&#xD;
Mupirocin: Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Projects</name_or_title>
      <organization>Destiny Pharma</organization>
      <phone>+44 (0)1273 704440</phone>
      <email>medinfo@destinypharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

